We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+2.35%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$7.71B
AUM Growth
-$201M
Cap. Flow
-$840M
Cap. Flow %
-10.9%
Top 10 Hldgs %
39.08%
Holding
169
New
28
Increased
15
Reduced
34
Closed
19

Top Buys

Rank Stock Value
1
NAUT icon
Nautilus Biotechnolgy
NAUT
+$96.5M
2
UTHR icon
United Therapeutics
UTHR
+$84.1M
3
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$79.6M
4
ZY
Zymergen Inc. Common Stock
ZY
+$64.5M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$60M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.3M
2
ALLO icon
Allogene Therapeutics
ALLO
+$40.4M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$39.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$36.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$35.4M

Sector Composition

Rank Sector Weight
1 Healthcare 84.87%
2 Financials 0.45%
3 Industrials 0.17%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$515M 6.68%
3,185,898
-288,607
-8% -$46.3M
BBIO icon
2
BridgeBio Pharma
BBIO
$16.6B
$473M 6.14%
7,756,928
– –
SWTX
3
DELISTED
SpringWorks Therapeutics
SWTX
$400M 5.19%
4,849,912
– –
IOVA icon
4
Iovance Biotherapeutics
IOVA
$2.04B
$285M 3.7%
10,959,772
+2,307,987
+27% +$60M
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$223M 2.89%
23,121,329
+260,000
+1% +$2.54M
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$186M 2.41%
1,985,002
-65,000
-3% -$5.98M
VBIV
7
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$184M 2.39%
1,834,749
– –
LABP
8
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$172M 2.23%
1,486,992
– –
NVTA
9
DELISTED
Invitae Corporation
NVTA
$163M 2.11%
4,818,801
-541,872
-10% -$17.6M
ZYME icon
10
Zymeworks
ZYME
$1.63B
$149M 1.94%
4,305,600
-25,268
-0.6% -$802K
GBT
11
DELISTED
Global Blood Therapeutics, Inc.
GBT
$145M 1.89%
4,152,689
-905,953
-18% -$35.4M
NVRO
12
DELISTED
NEVRO CORP.
NVRO
$136M 1.76%
818,760
+6,606
+0.8% +$1.03M
RCKT icon
13
Rocket Pharmaceuticals
RCKT
$337M
$122M 1.58%
2,751,603
-116,168
-4% -$5.05M
OM icon
14
Outset Medical
OM
$86.4M
$119M 1.55%
159,169
– –
CERE
15
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$119M 1.54%
4,643,095
– –
ALDX icon
16
Aldeyra Therapeutics
ALDX
$95.9M
$112M 1.46%
9,903,879
+1,200,000
+14% +$14.4M
UTHR icon
17
United Therapeutics
UTHR
$25.9B
$111M 1.44%
616,802
+441,802
+252% +$84.1M
MGTX icon
18
MeiraGTx Holdings
MGTX
$1.08B
$108M 1.4%
6,948,277
+15,000
+0.2% +$214K
NAUT icon
19
Nautilus Biotechnolgy
NAUT
$141M
$90M 1.17%
+8,911,151
New +$96.5M
CCCC icon
20
C4 Therapeutics
CCCC
$389M
$85.5M 1.11%
2,258,566
-900,000
-28% -$32.2M
OMIC
21
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$84.7M 1.1%
+102,762
New +$79.6M
ALBO
22
DELISTED
Albireo Pharma Inc
ALBO
$83M 1.08%
2,360,139
– –
RXDX
23
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$81.4M 1.06%
3,314,032
– –
NBIX icon
24
Neurocrine Biosciences
NBIX
$18.3B
$79M 1.03%
811,832
-130,000
-14% -$12.5M
RAPT
25
DELISTED
RAPT Therapeutics
RAPT
$78.7M 1.02%
309,458
-227
-0.1% -$42.4K
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Perceptive Advisors held 169 positions worth $7.71B, down 2.5% from $7.91B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Perceptive Advisors withdrew a net $840M in Q2 2021, closing 19 positions and reducing 34 holdings. Its most notable exit was Allogene Therapeutics, an estimated $40.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 80% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in Nautilus Biotechnolgy worth $90M.

  • Perceptive Advisors's largest Q2 2021 buy was Nautilus Biotechnolgy: 8,911,151 shares worth $90M.
  • Perceptive Advisors added most to United Therapeutics in Q2 2021, an estimated $84.1M increase.
  • Perceptive Advisors's biggest Q2 2021 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $46.3M.
  • Perceptive Advisors fully exited Allogene Therapeutics in Q2 2021, selling an estimated $40.4M.
  • Perceptive Advisors's ten largest holdings make up 39% of its $7.71B portfolio in Q2 2021.
  • Perceptive Advisors opened 28 new positions and closed 19 in Q2 2021.
  • Perceptive Advisors's portfolio value fell 2.5% quarter-over-quarter to $7.71B.

Based on Perceptive Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.